Cardiac Marker Testing Market Size, Share, Trends, Industry Analysis Report: By Product (Reagents & Kits and Instruments), Biomarker Type, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecas

The cardiac marker testing market size is expected to reach USD 11,771.28 million by 2034, according to a new study by Polaris Market Research. The report “Cardiac Marker Testing Market Size, Share, Trends, Industry Analysis Report: By Product (Reagents & Kits and Instruments), Biomarker Type, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Cardiac marker testing is a diagnostic process used to measure specific biomarkers in the blood that indicate cardiac conditions such as myocardial infarction, heart failure, and acute coronary syndrome. The market is experiencing growth due to the rising prevalence of cardiovascular diseases, increasing demand for high-sensitivity diagnostic tests, and advancements in point-of-care testing solutions. Key drivers include the aging population, growing awareness of early disease detection, and the integration of artificial intelligence (AI) in diagnostics.

Cardiac marker testing market opportunities exist in emerging markets where healthcare infrastructure is expanding. Further, trends such as multiplex assays and personalized medicine are shaping the market landscape. Overall, continuous innovation, regulatory approvals, and strategic collaborations are fueling market expansion and improving diagnostic accuracy for better patient outcomes.

Cardiac Marker Testing Market Report Highlights

The cardiac marker testing market, by product, is segmented into reagents & kits and instruments. The reagents & kits segment dominated the cardiac marker testing market share in 2024. This dominance is attributed to their widespread use in laboratory settings, offering high sensitivity and specificity in detecting cardiac biomarkers, which ensures accurate diagnosis of cardiovascular conditions.

The cardiac marker testing market, based on biomarker type, is segmented into troponin I & T, creatine kinase-MB (CK-MB), natriuretic peptide, myoglobin, high sensitivity c-reactive protein, and other cardiac biomarkers. The troponin I & T segment dominated the market share in 2024. Troponins are highly specific and sensitive biomarkers for myocardial injury, making them the preferred choice for diagnosing acute coronary syndromes.

By end user, the laboratory testing facilities segment accounts for the largest share due to widespread adoption in hospitals and diagnostic centers. However, the point-of-care testing facilities segment is growing rapidly due to the rising demand for quick and portable testing solutions.

North America dominated the cardiac marker testing market revenue share in 2024, driven by well-established healthcare infrastructure and high adoption of advanced diagnostics. However, Asia Pacific is the fastest-growing regional market due to increasing cardiovascular disease prevalence and expanding healthcare access.

Several key players in the cardiac marker testing market are actively contributing to advancements in diagnostic solutions. These include Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Siemens Healthineers AG; Danaher Corporation; bioMérieux SA; Ortho Clinical Diagnostics; Randox Laboratories Ltd.; Beckman Coulter, Inc. (a subsidiary of Danaher Corporation); DiaSorin S.p.A.; Thermo Fisher Scientific Inc.; Becton, Dickinson and Company; PerkinElmer Inc.; Quidel Corporation; CardioGenics Holdings Inc.; and LSI Medience Corporation.

Polaris Market Research has segmented the cardiac marker testing market report on the basis of product, biomarker type, end user, and region:

By Product Outlook (Revenue – USD Million, 2020–2034)

Reagents & Kits

Instruments

By Biomarker Type Outlook (Revenue – USD Million, 2020–2034)

Troponin I & T

Creatine Kinase-MB (CK-MB)

Natriuretic Peptide

Myoglobin

High Sensitivity C-Reactive Protein

Other Cardiac Biomarkers

By End User Outlook (Revenue – USD Million, 2020–2034)

Laboratory Testing Facilities

Point-of-Care Testing Facilities

Academic Institutions

By Regional Outlook (Revenue – USD Million, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America